taurine has been researched along with Sepsis in 32 studies
Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study shows that catheter filling with a solution containing the antimicrobial taurolidine may significantly reduce the incidence of catheter-related sepsis." | 9.11 | Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. ( Betjes, MG; van Agteren, M, 2004) |
| "Although reports of decreased plasma taurine in trauma, sepsis and critical illness are available, very little is known about the relationships among changes in plasma taurine, other amino acid levels and metabolic variables." | 9.09 | The relationship between plasma taurine and other amino acid levels in human sepsis. ( Boldrini, G; Castagneto, M; Chiarla, C; Giovannini, I; Siegel, JH, 2000) |
| " We investigated whether taurine, an endogenous antioxidant and vasodilator, could attenuate the deleterious effects of endotoxin in a mouse model of sepsis." | 7.74 | The effect of taurine on mesenteric blood flow and organ injury in sepsis. ( Akbiyik, F; Atilla, P; Balkanci, ZD; Cakar, N; Erdem, A; Guc, MO; Iskit, AB; Sevgili, AM, 2008) |
| "This study has been performed to characterize the relationship between changes in plasma taurine (TAU) and hemodynamic patterns in sepsis." | 7.70 | Taurine and pulmonary hemodynamics in sepsis. ( Boldrini, G; Castagneto, M; Chiarla, C; Giovannini, I; Siegel, JH, 2000) |
| "Taurine is an intracellular free amino acid that has anti-inflammatory and antioxidant effects." | 5.72 | Mechanism of taurine reducing inflammation and organ injury in sepsis mice. ( Deng, S; Hao, Y; Li, R; Ma, Y; Qin, Q; Ran, C; Zhang, J; Zhang, Y; Zhu, L, 2022) |
| "The pathogenesis of sepsis is characterized by an overwhelming systemic inflammatory response that can lead to multiple organ failure." | 5.36 | Effects of N-acetylcysteine/deferoxamine, taurine and RC-3095 on respiratory chain complexes and creatine kinase activities in rat brain after sepsis. ( Cassol, OJ; Dal-Pizzol, F; Ferreira, GK; Gonçalves, CL; Petronilho, FC; Rezin, GT; Roesler, R; Scaini, G; Schwartsmann, G; Streck, EL, 2010) |
| "[35S]Taurine contents were significantly lower only in kidneys, spleen and gastrointestinal tract of septic rats." | 5.30 | Metabolism of cysteine is modified during the acute phase of sepsis in rats. ( Breuillé, D; Malmezat, T; Mirand, PP; Obled, C; Pouyet, C, 1998) |
| "The incidence and cost of treatment of catheter sepsis occurring in all patients receiving haemodialysis via a line were investigated over 6-month periods before and after introducing the taurolidine/citrate line-locking agent." | 5.13 | A new haemodialysis catheter-locking agent reduces infections in haemodialysis patients. ( Cahill, J; Gerrish, M; Little, J; Taylor, C, 2008) |
| "This study shows that catheter filling with a solution containing the antimicrobial taurolidine may significantly reduce the incidence of catheter-related sepsis." | 5.11 | Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. ( Betjes, MG; van Agteren, M, 2004) |
| "Although reports of decreased plasma taurine in trauma, sepsis and critical illness are available, very little is known about the relationships among changes in plasma taurine, other amino acid levels and metabolic variables." | 5.09 | The relationship between plasma taurine and other amino acid levels in human sepsis. ( Boldrini, G; Castagneto, M; Chiarla, C; Giovannini, I; Siegel, JH, 2000) |
| " Taurolock (Bio-Implant HealthCare, Winsen, Germany), which contains taurolidine, is being marketed as a central venous catheter lock solution for decreasing the risk of catheter sepsis." | 4.84 | Taurolidine and catheter-related bloodstream infection: a systematic review of the literature. ( Bradshaw, JH; Puntis, JW, 2008) |
| " Incidence and type of sepsis were reviewed for 8 to 12 months pre- (when heparin was used) and 2 to 33 months postintroduction of the taurolidine catheter lock." | 3.78 | Significant reduction in central venous catheter-related bloodstream infections in children on HPN after starting treatment with taurolidine line lock. ( Brind, J; Chu, HP; Hill, S; Tomar, R, 2012) |
| " We investigated whether taurine, an endogenous antioxidant and vasodilator, could attenuate the deleterious effects of endotoxin in a mouse model of sepsis." | 3.74 | The effect of taurine on mesenteric blood flow and organ injury in sepsis. ( Akbiyik, F; Atilla, P; Balkanci, ZD; Cakar, N; Erdem, A; Guc, MO; Iskit, AB; Sevgili, AM, 2008) |
| "This study has been performed to characterize the relationship between changes in plasma taurine (TAU) and hemodynamic patterns in sepsis." | 3.70 | Taurine and pulmonary hemodynamics in sepsis. ( Boldrini, G; Castagneto, M; Chiarla, C; Giovannini, I; Siegel, JH, 2000) |
| "Taurolidine lock was also safe and effective in treating device colonization." | 1.91 | Taurolidine lock in the treatment of colonization and infection of totally implanted venous access devices in cancer patients. ( Bottos, P; Brescia, F; Da Ros, V; Fabiani, F; Moreal, C; Nadalini, E; Pittiruti, M; Scoppettuolo, G; Zanier, C, 2023) |
| "Taurine is an intracellular free amino acid that has anti-inflammatory and antioxidant effects." | 1.72 | Mechanism of taurine reducing inflammation and organ injury in sepsis mice. ( Deng, S; Hao, Y; Li, R; Ma, Y; Qin, Q; Ran, C; Zhang, J; Zhang, Y; Zhu, L, 2022) |
| "Taurine (Tau) is an abundant amino acid in polymorphonuclear leukocytes that react with hypochlorous acid to form taurine chloramine (TauCl) under inflammatory conditions." | 1.56 | Taurine Chloramine decreases cell viability and cytokine production in blood and spleen lymphocytes from septic rats. ( Dal-Pizzol, F; Dall'igna, DM; Luz, JMD; Michels, M; Vuolo, F, 2020) |
| "Sepsis was induced by caecum ligation and puncture (CLP)." | 1.42 | Gene silencing of non-obese diabetic receptor family (NLRP3) protects against the sepsis-induced hyper-bile acidaemia in a rat model. ( Chen, J; Ding, C; Gu, G; Hu, D; Li, J; Liu, S; Ren, J; Wang, G; Wu, X; Wu, Y; Zhou, B, 2015) |
| "The pathogenesis of sepsis is characterized by an overwhelming systemic inflammatory response that can lead to multiple organ failure." | 1.36 | Effects of N-acetylcysteine/deferoxamine, taurine and RC-3095 on respiratory chain complexes and creatine kinase activities in rat brain after sepsis. ( Cassol, OJ; Dal-Pizzol, F; Ferreira, GK; Gonçalves, CL; Petronilho, FC; Rezin, GT; Roesler, R; Scaini, G; Schwartsmann, G; Streck, EL, 2010) |
| "After multiple trauma taurine decreased significantly in plasma in thirty-two patients as well as within the neutrophil and does not recover in sepsis." | 1.33 | Relationship of taurine and other amino acids in plasma and in neutrophils of septic trauma patients. ( Engel, JM; Hempelmann, G; Kärcher, B; Little, S; Löhr, T; Menges, T; Mühling, J; Weiss, S, 2006) |
| "[35S]Taurine contents were significantly lower only in kidneys, spleen and gastrointestinal tract of septic rats." | 1.30 | Metabolism of cysteine is modified during the acute phase of sepsis in rats. ( Breuillé, D; Malmezat, T; Mirand, PP; Obled, C; Pouyet, C, 1998) |
| "Taurolidine is an anti-infective agent with an unusually broad spectrum of effectivity against gram-positive and gram-negative bacteria, anaerobic organisms, and fungi." | 1.30 | [The influence of taurolidine on physiological and pathological blood coagulation and implications for its use]. ( Reinmüller, J, 1999) |
| " However, by increasing the dosage of taurolin, survival is prolonged and mortality reduced." | 1.26 | The in vitro and in vivo activity of taurolin against anaerobic pathogenic organisms. ( Brodhage, H; Browne, MK; Leslie, GB; Pfirrman, RW, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.13) | 18.7374 |
| 1990's | 3 (9.38) | 18.2507 |
| 2000's | 11 (34.38) | 29.6817 |
| 2010's | 8 (25.00) | 24.3611 |
| 2020's | 9 (28.13) | 2.80 |
| Authors | Studies |
|---|---|
| van den Bosch, CH | 1 |
| Jeremiasse, B | 1 |
| van der Bruggen, JT | 1 |
| Frakking, FNJ | 1 |
| Loeffen, YGT | 1 |
| van de Ven, CP | 1 |
| van der Steeg, AFW | 1 |
| Fiocco, MF | 1 |
| van de Wetering, MD | 1 |
| Wijnen, MHWA | 1 |
| Vernon-Roberts, A | 1 |
| Lopez, RN | 1 |
| Frampton, CM | 1 |
| Day, AS | 1 |
| Ma, Y | 1 |
| Zhang, Y | 1 |
| Li, R | 1 |
| Deng, S | 1 |
| Qin, Q | 1 |
| Ran, C | 1 |
| Hao, Y | 1 |
| Zhang, J | 1 |
| Zhu, L | 1 |
| Huang, J | 1 |
| Ita, M | 1 |
| Zhou, H | 1 |
| Zhao, H | 1 |
| Hassan, F | 1 |
| Bai, Z | 1 |
| O'Leary, DP | 1 |
| Li, Y | 1 |
| Redmond, HP | 1 |
| Wang, JH | 1 |
| Wang, J | 2 |
| Supinski, GS | 1 |
| Wang, L | 1 |
| Schroder, EA | 1 |
| Callahan, LAP | 1 |
| Xu, D | 1 |
| Liao, S | 1 |
| Lv, Y | 1 |
| Kong, L | 1 |
| Dall'igna, DM | 1 |
| Luz, JMD | 1 |
| Vuolo, F | 1 |
| Michels, M | 1 |
| Dal-Pizzol, F | 2 |
| Brescia, F | 1 |
| Pittiruti, M | 1 |
| Scoppettuolo, G | 1 |
| Zanier, C | 1 |
| Nadalini, E | 1 |
| Bottos, P | 1 |
| Moreal, C | 1 |
| Da Ros, V | 1 |
| Fabiani, F | 1 |
| Chen, J | 2 |
| Xue, X | 2 |
| Cai, J | 1 |
| Jia, L | 2 |
| Sun, B | 1 |
| Zhao, W | 2 |
| Yang, HJ | 1 |
| Xu, WX | 1 |
| Cai, JQ | 1 |
| Guo, RJ | 1 |
| Cao, CC | 1 |
| Klek, S | 2 |
| Szczepanek, K | 2 |
| Hermanowicz, A | 1 |
| Galas, A | 1 |
| Wu, Y | 1 |
| Ren, J | 1 |
| Zhou, B | 1 |
| Ding, C | 1 |
| Wang, G | 1 |
| Gu, G | 1 |
| Wu, X | 1 |
| Liu, S | 1 |
| Hu, D | 1 |
| Li, J | 1 |
| Olthof, ED | 1 |
| Broekman, MM | 1 |
| Wanten, GJ | 1 |
| Bradshaw, JH | 1 |
| Puntis, JW | 1 |
| Taylor, C | 1 |
| Cahill, J | 1 |
| Gerrish, M | 1 |
| Little, J | 1 |
| Cassol, OJ | 1 |
| Rezin, GT | 1 |
| Petronilho, FC | 1 |
| Scaini, G | 1 |
| Gonçalves, CL | 1 |
| Ferreira, GK | 1 |
| Roesler, R | 1 |
| Schwartsmann, G | 1 |
| Streck, EL | 1 |
| Chu, HP | 1 |
| Brind, J | 1 |
| Tomar, R | 1 |
| Hill, S | 1 |
| Xu, ZW | 1 |
| Li, YS | 1 |
| Manocha, S | 1 |
| Feinstein, D | 1 |
| Kumar, A | 2 |
| Betjes, MG | 1 |
| van Agteren, M | 1 |
| Engel, JM | 1 |
| Mühling, J | 1 |
| Weiss, S | 1 |
| Kärcher, B | 1 |
| Löhr, T | 1 |
| Menges, T | 1 |
| Little, S | 1 |
| Hempelmann, G | 1 |
| Erdem, A | 1 |
| Sevgili, AM | 1 |
| Akbiyik, F | 1 |
| Atilla, P | 1 |
| Cakar, N | 1 |
| Balkanci, ZD | 1 |
| Iskit, AB | 1 |
| Guc, MO | 1 |
| Malmezat, T | 1 |
| Breuillé, D | 1 |
| Pouyet, C | 1 |
| Mirand, PP | 1 |
| Obled, C | 1 |
| Reinmüller, J | 1 |
| Hung, CR | 1 |
| Hung, PC | 1 |
| Chiarla, C | 2 |
| Giovannini, I | 2 |
| Siegel, JH | 2 |
| Boldrini, G | 2 |
| Castagneto, M | 2 |
| Sodemann, K | 1 |
| Polaschegg, HD | 1 |
| Feldmer, B | 1 |
| Quarello, F | 1 |
| Forneris, G | 1 |
| Btaiche, IF | 1 |
| Khalidi, N | 1 |
| Browne, MK | 1 |
| Leslie, GB | 1 |
| Pfirrman, RW | 1 |
| Brodhage, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective, Randomized, Controlled Trial Evaluating the Efficacy of a Lock-therapy With a Solution of Taurolidine/Citrate (TauroLock) vs Standard Saline Solution for the Primary Prevention of Catheter-related Infections (CLI) in Adult Patients Wtih a Non[NCT02279121] | 162 participants (Actual) | Interventional | 2014-11-30 | Completed | |||
| A Randomised Study of Taurolock for the Locking of Tunneled Central Venous Catheters in Children With Malignant Diseases.[NCT00735813] | Phase 3 | 129 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Calciuric Effect and Cyclic Parenteral Nutrition in Preterm Infants[NCT00711763] | 1 participants (Actual) | Observational | 2008-07-31 | Terminated (stopped due to failure to recruit more patients and lack of supporting personnel.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for taurine and Sepsis
| Article | Year |
|---|---|
The efficacy of taurolidine containing lock solutions for the prevention of central-venous-catheter-related bloodstream infections: a systematic review and meta-analysis.
Topics: Catheter-Related Infections; Catheterization, Central Venous; Central Venous Catheters; Humans; Rand | 2022 |
Meta-analysis of the efficacy of taurolidine in reducing catheter-related bloodstream infections for patients receiving parenteral nutrition.
Topics: Catheter-Related Infections; Catheterization, Central Venous; Central Venous Catheters; Humans; Pare | 2022 |
Taurolidine and catheter-related bloodstream infection: a systematic review of the literature.
Topics: Anti-Infective Agents; Catheterization, Central Venous; Equipment Contamination; Evidence-Based Medi | 2008 |
Pathogenesis and treatment of parenteral nutrition-associated liver disease.
Topics: Animals; Chemical and Drug Induced Liver Injury; Choline Deficiency; Enteral Nutrition; Fat Emulsion | 2012 |
Novel therapies for sepsis: antiendotoxin therapies.
Topics: Acute-Phase Proteins; Antibodies, Monoclonal; Carrier Proteins; Endotoxins; Humans; Lipopolysacchari | 2002 |
Prevention of hemodialysis catheter-related bloodstream infection using an antimicrobial lock.
Topics: Anti-Infective Agents, Local; Catheters, Indwelling; Citric Acid; Equipment Contamination; Equipment | 2002 |
Parenteral nutrition-associated liver complications in children.
Topics: Alkaline Phosphatase; Anti-Bacterial Agents; Bilirubin; Carnitine; Child; Cholestasis; gamma-Glutamy | 2002 |
4 trials available for taurine and Sepsis
| Article | Year |
|---|---|
Taurolidine lock in home parenteral nutrition in adults: results from an open-label randomized controlled clinical trial.
Topics: Adult; Anti-Infective Agents; Bacteremia; Catheter-Related Infections; Catheterization, Central Veno | 2015 |
A new haemodialysis catheter-locking agent reduces infections in haemodialysis patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Local; Catheters, Indwelling; Chi-Square Dist | 2008 |
Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution.
Topics: Anti-Infective Agents; Bacterial Infections; Catheterization, Central Venous; Catheters, Indwelling; | 2004 |
Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution.
Topics: Anti-Infective Agents; Bacterial Infections; Catheterization, Central Venous; Catheters, Indwelling; | 2004 |
Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution.
Topics: Anti-Infective Agents; Bacterial Infections; Catheterization, Central Venous; Catheters, Indwelling; | 2004 |
Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution.
Topics: Anti-Infective Agents; Bacterial Infections; Catheterization, Central Venous; Catheters, Indwelling; | 2004 |
The relationship between plasma taurine and other amino acid levels in human sepsis.
Topics: Adult; Amino Acids; Female; Humans; Injury Severity Score; Male; Parenteral Nutrition, Total; Regres | 2000 |
21 other studies available for taurine and Sepsis
| Article | Year |
|---|---|
Mechanism of taurine reducing inflammation and organ injury in sepsis mice.
Topics: Animals; Inflammation; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Neutrophils; Sepsis; Taurine; | 2022 |
Autophagy induced by taurolidine protects against polymicrobial sepsis by promoting both host resistance and disease tolerance.
Topics: Animals; Autophagy; Mice; Phagocytosis; Sepsis; Taurine; Thiadiazines | 2022 |
Taurine administration ablates sepsis induced diaphragm weakness.
Topics: Animals; Diaphragm; Mice; Muscle Weakness; Oxidative Stress; Sepsis; Taurine | 2020 |
NMR-based metabolomics approach reveals effects of antioxidant nutrients in sepsis-induced changes in rat liver injury.
Topics: Animals; Antioxidants; Ascorbic Acid; Disease Models, Animal; Glutathione; Liver Diseases; Magnetic | 2020 |
Taurine Chloramine decreases cell viability and cytokine production in blood and spleen lymphocytes from septic rats.
Topics: Animals; Cell Survival; Cells, Cultured; Cytokines; Lymphocytes; Rats; Sepsis; Spleen; Taurine | 2020 |
Taurolidine lock in the treatment of colonization and infection of totally implanted venous access devices in cancer patients.
Topics: Catheter-Related Infections; Catheterization, Central Venous; Central Venous Catheters; Humans; Neop | 2023 |
Protective effect of taurine on sepsis‑induced lung injury via inhibiting the p38/MAPK signaling pathway.
Topics: Acute Lung Injury; Animals; Disease Models, Animal; Imidazoles; Lung; Male; Malondialdehyde; MAP Kin | 2021 |
Taurine enhances the protective effect of Dexmedetomidine on sepsis-induced acute lung injury via balancing the immunological system.
Topics: Acute Lung Injury; Animals; Apoptosis; Caspase 3; Dexmedetomidine; Immune System; Inflammation; Ki-6 | 2018 |
Gene silencing of non-obese diabetic receptor family (NLRP3) protects against the sepsis-induced hyper-bile acidaemia in a rat model.
Topics: Animals; Bile Acids and Salts; Carrier Proteins; Cytokines; Gene Silencing; Glycine; Hepatocytes; Hy | 2015 |
Do we know the benefits of a taurolidine lock in adult home parenteral nutrition patients with a low infection rate?
Topics: Anti-Infective Agents; Catheter-Related Infections; Catheterization, Central Venous; Central Venous | 2015 |
Response to Olthof et al.
Topics: Anti-Infective Agents; Catheter-Related Infections; Catheterization, Central Venous; Central Venous | 2015 |
Effects of N-acetylcysteine/deferoxamine, taurine and RC-3095 on respiratory chain complexes and creatine kinase activities in rat brain after sepsis.
Topics: Acetylcysteine; Animals; Bombesin; Brain; Creatine Kinase; Deferoxamine; Electron Transport; Male; P | 2010 |
Significant reduction in central venous catheter-related bloodstream infections in children on HPN after starting treatment with taurolidine line lock.
Topics: Adolescent; Adult; Anti-Infective Agents; Anticoagulants; Catheter-Related Infections; Catheterizati | 2012 |
Relationship of taurine and other amino acids in plasma and in neutrophils of septic trauma patients.
Topics: Adult; Amino Acids; Aspartic Acid; Glutamic Acid; Humans; Middle Aged; Neutrophils; Retrospective St | 2006 |
The effect of taurine on mesenteric blood flow and organ injury in sepsis.
Topics: Animals; Blood Flow Velocity; Disease Models, Animal; Endotoxins; Free Radicals; Glutathione; Inject | 2008 |
Metabolism of cysteine is modified during the acute phase of sepsis in rats.
Topics: Acute-Phase Reaction; Animals; Body Weight; Cysteine; Escherichia coli Infections; Glutathione; Male | 1998 |
[The influence of taurolidine on physiological and pathological blood coagulation and implications for its use].
Topics: Anti-Infective Agents, Local; Bacterial Infections; Blood Coagulation; Gram-Negative Bacteria; Gram- | 1999 |
Protective effects of several amino acid-nutrients on gastric hemorrhagic erosions in acid-irrigated stomachs of septic rats.
Topics: Acids; Amino Acids; Animals; Arginine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gastric | 1999 |
Taurine and pulmonary hemodynamics in sepsis.
Topics: Adolescent; Adult; Amino Acids; Atrial Function, Right; Blood Pressure; Female; Hemodynamics; Humans | 2000 |
Two years' experience with Dialock and CLS (a new antimicrobial lock solution).
Topics: Adult; Anti-Infective Agents; Anticoagulants; Catheterization, Central Venous; Catheters, Indwelling | 2001 |
The in vitro and in vivo activity of taurolin against anaerobic pathogenic organisms.
Topics: Animals; Bacterial Infections; Bacteroides; Bacteroides Infections; Clostridium Infections; Clostrid | 1977 |